Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.

Chilton RJ, Dungan KM, Shubrook JH, Umpierrez GE.

Prim Care Diabetes. 2019 Nov 5. pii: S1751-9918(19)30075-0. doi: 10.1016/j.pcd.2019.09.008. [Epub ahead of print] Review.

2.

Cardio-Renal Protection with SGLT2: Lessons from the Cardiovascular Outcome Trials.

Silva-Cardoso J, Sheikh O, Nashawi M, Pham S, Gallegos KM, Dinkha LR, Chilton RJ.

J Diabetes. 2019 Nov 5. doi: 10.1111/1753-0407.13007. [Epub ahead of print] Review.

PMID:
31688975
3.

Management of Right Atrial Thrombus. Where's the Evidence?

Sheikh O, Gulick D, Saenger E, Parmar R, Chilton R, Bailey S.

Curr Cardiol Rev. 2019 Oct 23. doi: 10.2174/1573403X15666191023114546. [Epub ahead of print]

PMID:
31657680
4.

A new perspective on lowering CV risk from hypoglycaemia.

Solis-Herrera C, Sheikh O, Chilton R.

Eur Heart J. 2019 Oct 11. pii: ehz730. doi: 10.1093/eurheartj/ehz730. [Epub ahead of print] No abstract available.

PMID:
31605128
5.

Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.

Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R.

Diabetol Metab Syndr. 2019 Sep 26;11:80. doi: 10.1186/s13098-019-0476-0. eCollection 2019. Review.

6.

Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.

Chilton RJ.

Diabetes Obes Metab. 2020 Jan;22(1):16-29. doi: 10.1111/dom.13854. Epub 2019 Aug 30. Review.

PMID:
31407866
7.

Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial.

Sheikh O, Vande Hei AG, Battisha A, Hammad T, Pham S, Chilton R.

Cardiovasc Diabetol. 2019 Jun 24;18(1):84. doi: 10.1186/s12933-019-0887-0. Review.

8.

Glucose lowering and vascular protective effects of cycloset added to GLP-1 receptor agonists in patients with type 2 diabetes.

Alatrach M, Agyin C, Adams J, Chilton R, Triplitt C, DeFronzo RA, Cersosimo E.

Endocrinol Diabetes Metab. 2018 Aug 15;1(4):e00034. doi: 10.1002/edm2.34. eCollection 2018 Oct.

9.

Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control.

Clarke GD, Molina-Wilkins M, Solis-Herrera C, Mendez V, Monroy A, Cersosimo E, Chilton RJ, Abdul-Ghani M, DeFronzo RA.

Endocrinol Diabetes Metab. 2018 Apr 6;1(2):e00014. doi: 10.1002/edm2.14. eCollection 2018 Apr.

10.

PCSK9 inhibitors and diabetes: Translational biology to clinical practice.

Chilton RJ, Oliveros R, Gallegos KM, Pham S.

Diabetes Obes Metab. 2019 Mar;21(3):451-453. doi: 10.1111/dom.13600. Epub 2019 Jan 17. No abstract available.

PMID:
30520245
11.

Lipids as risk markers for type 2 diabetes.

Bloomgarden Z, Chilton R.

J Diabetes. 2019 Mar;11(3):176-178. doi: 10.1111/1753-0407.12880. Epub 2018 Dec 18. No abstract available.

PMID:
30479008
12.

The Evolving Role of the Cardiologist in the Management of Type 2 Diabetes.

Chilton RJ, Gallegos KM, Silva-Cardoso J, Oliveros R, Pham S.

Curr Diab Rep. 2018 Nov 8;18(12):144. doi: 10.1007/s11892-018-1114-1. Review.

PMID:
30406850
13.

Comprehensive assessment of cryogenic storage risk and quality management concerns: best practice guidelines for ART labs.

Schiewe MC, Freeman M, Whitney JB, VerMilyea MD, Jones A, Aguirre M, Leisinger C, Adaniya G, Synder N, Chilton R, Behnke EJ.

J Assist Reprod Genet. 2019 Jan;36(1):5-14. doi: 10.1007/s10815-018-1310-6. Epub 2018 Sep 19. Review.

14.

Myocardial considerations in type 2 diabetes: 2018.

Chilton R, Lin C, Gallegos KM, Pham S.

J Diabetes. 2018 Oct;10(10):784-788. doi: 10.1111/1753-0407.12788. Epub 2018 Jul 22. No abstract available.

PMID:
30033584
15.

Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance.

Shunmoogam N, Naidoo P, Chilton R.

Vasc Health Risk Manag. 2018 Jun 18;14:137-143. doi: 10.2147/VHRM.S165173. eCollection 2018. Review.

16.

Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era.

Krentz AJ, Chilton R.

Cardiovasc Endocrinol Metab. 2018 Feb 14;7(1):2-3. doi: 10.1097/XCE.0000000000000150. eCollection 2018 Mar. No abstract available.

17.

Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.

Marso SP, Hardy E, Han J, Wang H, Chilton RJ.

Diabetes Ther. 2018 Apr;9(2):551-564. doi: 10.1007/s13300-018-0370-z. Epub 2018 Feb 3.

18.

Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.

Del Prato S, Chilton R.

Diabetes Obes Metab. 2018 Apr;20(4):786-799. doi: 10.1111/dom.13169. Epub 2017 Dec 21. Review.

19.

Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813-820.

Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ.

Diabetes Care. 2017 Nov;40(11):1606. doi: 10.2337/dc17-er11. Epub 2017 Sep 8. No abstract available.

20.

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.

Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA.

Diabetes Care. 2017 Nov;40(11):1530-1536. doi: 10.2337/dc17-0078. Epub 2017 Aug 28.

21.

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?

Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ.

Diabetes Care. 2017 Jul;40(7):813-820. doi: 10.2337/dc16-2736. Erratum in: Diabetes Care. 2017 Sep 8;:.

22.

EMPA-REG OUTCOME: The Cardiologist's Point of View.

Pham SV, Chilton RJ.

Am J Cardiol. 2017 Jul 1;120(1S):S53-S58. doi: 10.1016/j.amjcard.2017.05.011. Epub 2017 May 30. Review.

23.

Introduction.

Chilton RJ.

Am J Cardiol. 2017 Jul 1;120(1S):S1-S3. doi: 10.1016/j.amjcard.2017.05.008. Epub 2017 May 30. No abstract available.

24.

EMPA-REG OUTCOME: The Cardiologist's Point of View.

Pham SV, Chilton R.

Am J Med. 2017 Jun;130(6S):S57-S62. doi: 10.1016/j.amjmed.2017.04.006.

25.

Introduction.

Chilton R.

Am J Med. 2017 Jun;130(6S):S1-S3. doi: 10.1016/j.amjmed.2017.04.003. No abstract available.

26.

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.

Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R.

Ther Clin Risk Manag. 2017 May 3;13:603-611. doi: 10.2147/TCRM.S97619. eCollection 2017. Review.

27.

Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.

Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE.

Diabetes Obes Metab. 2017 Nov;19(11):1620-1624. doi: 10.1111/dom.12962. Epub 2017 Jul 7.

PMID:
28387058
28.

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.

Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.

Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3.

29.

Cardiac Manifestations of Congenital Generalized Lipodystrophy.

Sanon VP, Handelsman Y, Pham SV, Chilton R.

Clin Diabetes. 2016 Oct;34(4):181-186.

30.

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.

Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA.

Diabetes Care. 2016 May;39(5):717-25. doi: 10.2337/dc16-0041.

31.

Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.

DeFronzo RA, Chilton R, Norton L, Clarke G, Ryder RE, Abdul-Ghani M.

Diabetes Obes Metab. 2016 May;18(5):454-62. doi: 10.1111/dom.12652. Epub 2016 Apr 6. Review.

PMID:
26919068
32.

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, Broedl UC, Johansen OE.

Diab Vasc Dis Res. 2016 Mar;13(2):119-26. doi: 10.1177/1479164115616901.

33.

Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.

Tikkanen I, Chilton R, Johansen OE.

Curr Opin Nephrol Hypertens. 2016 Mar;25(2):81-6. doi: 10.1097/MNH.0000000000000199. Review.

PMID:
26808705
34.

Implementing health promotion programmes in schools: a realist systematic review of research and experience in the United Kingdom.

Pearson M, Chilton R, Wyatt K, Abraham C, Ford T, Woods HB, Anderson R.

Implement Sci. 2015 Oct 28;10:149. doi: 10.1186/s13012-015-0338-6. Review.

35.

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.

Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE.

Diabetes Obes Metab. 2015 Dec;17(12):1180-93. doi: 10.1111/dom.12572. Epub 2015 Oct 9.

36.

Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes.

Sanon VP, Sanon S, Pham SV, Chilton R.

Clin Diabetes. 2014 Jul;32(3):121-6. doi: 10.2337/diaclin.32.3.121. No abstract available.

37.

Understanding adolescent type 1 diabetes self-management as an adaptive process: A grounded theory approach.

Chilton R, Pires-Yfantouda R.

Psychol Health. 2015;30(12):1486-504. doi: 10.1080/08870446.2015.1062482. Epub 2015 Jul 13.

PMID:
26084198
38.

Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.

Johnson DA, Chilton R, Liker HR.

Postgrad Med. 2014 May;126(3):239-45. doi: 10.3810/pgm.2014.05.2772.

PMID:
24918808
39.

Aortic stiffness: pathophysiology, clinical implications, and approach to treatment.

Sethi S, Rivera O, Oliveros R, Chilton R.

Integr Blood Press Control. 2014 May 23;7:29-34. doi: 10.2147/IBPC.S59535. eCollection 2014. Review.

40.

Hypoglycemia from a cardiologist's perspective.

Sanon VP, Sanon S, Kanakia R, Yu H, Araj F, Oliveros R, Chilton R.

Clin Cardiol. 2014 Aug;37(8):499-504. doi: 10.1002/clc.22288. Epub 2014 Jun 4. Review.

41.

Integrative computational and experimental approaches to establish a post-myocardial infarction knowledge map.

Nguyen NT, Zhang X, Wu C, Lange RA, Chilton RJ, Lindsey ML, Jin YF.

PLoS Comput Biol. 2014 Mar 20;10(3):e1003472. doi: 10.1371/journal.pcbi.1003472. eCollection 2014 Mar.

42.

Applications of miRNA technology for atherosclerosis.

Toba H, Cortez D, Lindsey ML, Chilton RJ.

Curr Atheroscler Rep. 2014 Feb;16(2):386. doi: 10.1007/s11883-013-0386-9. Review.

43.

Interventions for acute coronary syndrome in young women and oral contraceptives.

Eshelbrenner C, Chilton R.

Catheter Cardiovasc Interv. 2013 Sep 1;82(3):394-5. doi: 10.1002/ccd.25113. No abstract available.

PMID:
24038977
44.

A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities.

Iyer RP, Lindsey ML, Chilton RJ.

J Clin Hypertens (Greenwich). 2013 Jul;15(7):455-7. doi: 10.1111/jch.12112. Epub 2013 Apr 29. No abstract available.

45.

Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus.

Chilton R.

Expert Rev Endocrinol Metab. 2013 Jul;8(4):345-349. doi: 10.1586/17446651.2013.811849.

PMID:
30736150
46.

New options for the treatment of obesity and type 2 diabetes mellitus (narrative review).

Henry RR, Chilton R, Garvey WT.

J Diabetes Complications. 2013 Sep-Oct;27(5):508-18. doi: 10.1016/j.jdiacomp.2013.04.011. Epub 2013 May 28. Review.

47.

Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium.

Yabluchanskiy A, Chilton RJ, Lindsey ML.

Congest Heart Fail. 2013 Jul-Aug;19(4):E5-8. doi: 10.1111/chf.12023. Epub 2013 Jan 25. Review. No abstract available.

48.

Matrix metalloproteinases: drug targets for myocardial infarction.

Yabluchanskiy A, Li Y, Chilton RJ, Lindsey ML.

Curr Drug Targets. 2013 Mar;14(3):276-86. Review.

49.

Imaging of vulnerable plaques using near-infrared spectroscopy for risk stratification of atherosclerosis.

Sanon S, Dao T, Sanon VP, Chilton R.

Curr Atheroscler Rep. 2013 Feb;15(2):304. doi: 10.1007/s11883-012-0304-6. Review.

PMID:
23299644
50.

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.

Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R.

Vasc Health Risk Manag. 2012;8:621-9. doi: 10.2147/VHRM.S37969. Epub 2012 Nov 12.

Supplemental Content

Loading ...
Support Center